U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C2H3O2.Mn
Molecular Weight 173.0261
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MANGANESE ACETATE

SMILES

[Mn++].CC([O-])=O.CC([O-])=O

InChI

InChIKey=UOGMEBQRZBEZQT-UHFFFAOYSA-L
InChI=1S/2C2H4O2.Mn/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula C2H3O2
Molecular Weight 59.044
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Mn
Molecular Weight 54.938
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm

Manganese citrate is generally recognized as safe direct food additive. Manganese citrate complex has being used in the determination of liver enzyme activities in the aging process and following treatment with aminoethylisothiuronium bromide hydrobromide (AET).

CNS Activity

Originator

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1430
Activator
1430
Activator
1430
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
Unknown

Approved Use

Manganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese.
Primary
Approved
8429
Unknown

Approved Use

Manganese is used for weak bones (osteoporosis).
Palliative
Approved
8429
Unknown

Approved Use

Early research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension.
Curative
Approved
8429
MANGANESE SULFATE

Approved Use

Manganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Primary
Approved
8429
MANGANESE SULFATE

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Cytochrome oxidase determination using a manganese citrate complex.
1970
Metabolism of l-Tyrosine to 4-Hydroxybenzaldehyde and 3-Bromo-4-Hydroxybenzaldehyde by Chloroplast-containing Fractions of Odonthalia floccosa (Esp.) Falk.
1979 Dec
Dietary calcium and manganese effects on menstrual cycle symptoms.
1993 May
Equilibrium and kinetics studies of reactions of manganese acetate, cobalt acetate, and bromide salts in acetic acid solutions.
2001 Jun 18
Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of managanese citrate as well as manganese and manganese transferrin.
2003 Jan
Persistent alterations in biomarkers of oxidative stress resulting from combined in utero and neonatal manganese inhalation.
2005 May
Decreased expression of inflammation-related genes following inhalation exposure to manganese.
2006 May
Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain.
2009 Sep
Expression profile analysis of antioxidative stress and developmental pathway genes in the manganese-exposed intertidal copepod Tigriopus japonicus with 6K oligochip.
2013 Aug
Chronic exposure to manganese sulfate leads to adverse dose-dependent effects on the neurobehavioral ability of rats.
2016 Nov
Top-Down Strategy to Synthesize Mesoporous Dual Carbon Armored MnO Nanoparticles for Lithium-Ion Battery Anodes.
2017 Apr 12
Patents

Patents

04048185
23
05089050
24
05261953
23
05629274
23
05700944
23
06136455
24
06548713
23
07091342
25
07384965
26
07544707
26
07598266
24
07615520
24
08460631
23
20020169331
23
20050222440
23
20060205615
24
20060205744
23
20090196809
23
20110203659
23
6589693
23
6627256
23
7435361
26
7687047
23
CA2165259A1
23
CA2517370C
23
DE102016209961
23
EP1627663A3
23
JP 2001058829 A
23
US 3585022 A
23
US20150218342
23
US2825631
23
US2916504
23
US2952519
26

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:13:39 GMT 2023
Edited
by admin
on Fri Dec 15 15:13:39 GMT 2023
Record UNII
0V6E9Q2I0Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MANGANESE ACETATE
MI   WHO-DD  
Systematic Name English
DIACETYLMANGANESE
Systematic Name English
ACETIC ACID, MANGANESE(II) SALT (2:1)
Common Name English
MANGANESE(II) ACETATE
Systematic Name English
MANGANOUS ACETATE [HSDB]
Common Name English
MANGANESE DIACETATE
Systematic Name English
MANGANESE(2+) ACETATE
Systematic Name English
Manganese acetate [WHO-DD]
Common Name English
MANGANOUS ACETATE
HSDB  
Common Name English
MANGANESE ACETATE [MI]
Common Name English
ACETIC ACID, MANGANESE(2+) SALT
Common Name English
Code System Code Type Description
HSDB
5734
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
NCI_THESAURUS
C87338
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
ECHA (EC/EINECS)
211-334-3
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
EPA CompTox
DTXSID5027279
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
DAILYMED
0V6E9Q2I0Y
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
PUBCHEM
12525
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
WIKIPEDIA
MANGANESE(II) ACETATE
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
CAS
638-38-0
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
MERCK INDEX
m7059
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
CONCEPT Dietary Supplement
SMS_ID
300000004000
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
FDA UNII
0V6E9Q2I0Y
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY
RXCUI
1370629
Created by admin on Fri Dec 15 15:13:39 GMT 2023 , Edited by admin on Fri Dec 15 15:13:39 GMT 2023
PRIMARY RxNorm
Related Record Type Details
Structure of MANGANOUS CATION
PARENT -> SALT/SOLVATE
Structure of MANGANESE ACETATE TETRAHYDRATE
SOLVATE->ANHYDROUS
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966